Valuation: ICAD

Market Cap 106M 91.34M 85.3M 78.25M 147M 10.05B 150M 1B 393M 5.04B 397M 388M 16.65B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 76.77M 71.69M 65.76M 124M 8.45B 126M 841M 330M 4.23B 333M 326M 14B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
12.73
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap.
7/17/25 Issuer sale

Director

1,553,657 5.8540%
7/17/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
7/17/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+51.76% 106M
+2.41%+3.43%+28.93%+8.48% 220B
+2.39%+5.02%+2.09%-20.03% 144B
+1.36%+7.21%-19.42%+24.57% 134B
+0.02%+5.52%-52.19%-3.43% 71.46B
+0.45%+4.24%+14.51%+15.07% 51.71B
+1.05%+7.19%-14.90%-17.86% 50.84B
+3.28%+5.49%+27.35%+14.37% 41.23B
+1.79%+7.83%+44.69%+39.33% 39.95B
+2.08%+5.51%-0.32%-2.91% 32.42B
Average +1.86%+5.14%+3.07%+10.93% 78.51B
Weighted average by Cap. +1.79%+5.27%+4.10%+5.05%

Financials

2023 2024
Net sales 17.32M 14.98M 13.99M 12.83M 24.14M 1.65B 24.52M 164M 64.42M 826M 65.03M 63.61M 2.73B 19.61M 16.96M 15.84M 14.53M 27.33M 1.87B 27.76M 186M 72.94M 935M 73.63M 72.02M 3.09B
Net income -4.85M -4.19M -3.92M -3.59M -6.76M -461M -6.86M -45.94M -18.03M -231M -18.2M -17.8M -764M -5.62M -4.86M -4.54M -4.16M -7.83M -534M -7.95M -53.22M -20.89M -268M -21.09M -20.63M -886M
Net Debt -21.21M -18.35M -17.13M -15.72M -29.56M -2.02B -30.03M -201M -78.89M -1.01B -79.64M -77.9M -3.34B -16.84M -14.57M -13.61M -12.48M -23.48M -1.6B -23.85M -160M -62.66M -804M -63.25M -61.87M -2.66B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock